Adcirca

Revenue jumped 62 percent, to $128.9 million, from $79.7 million, as sales of Remodulin grew and the FDA approved Tyvaso and Adcirca in 2009.

Google wins Rosetta Stone ruling; HGS posts loss; United Therapeutics has boost 2010

Elsewhere in the small-cap space, United Therapeutics added 7.89, or 12%, to $74.43, after the Silver Springs, Md., drug developer received FDA approval for Adcirca for a form of hypertension.

Russell 2000 Leaps 4.8%, Led by Home Builders 2009

Net product revenues, consisting of Remodulin, Tyvaso and Adcirca sales, increased 28.8% to $163.4 million in the reported quarter.

unknown title 2011

Meanwhile, newly launched products, Tyvaso and Adcirca, contributed $48.7 million and $12.4 million, respectively, to fourth quarter revenues.

unknown title 2011

The company's three main products, Remodulin, Adcirca and Tyvaso, are treatments for pulmonary arterial hypertension, a potentially life-threatening high-blood-pressure condition.

unknown title 2011

Meanwhile, Adcirca revenues are expected to reach $100 million in the next 18-24 months thereby bringing total revenues to more than $900 million during that time frame.

unknown title 2011

Revenues increased primarily due to the continued increase in the number of patients being prescribed Remodulin, price increases for Remodulin, and contributions from new products, Tyvaso and Adcirca.

unknown title 2011

Tyvaso and Adcirca should both keep contributing significantly to revenues with wider acceptance in the market.

unknown title 2011

Tyvaso accounted for $29.5 million in revenue and Adcirca added $8.6 million in the quarter, compared with no revenue in the year-ago period.

National Business News - Local Business News | bizjournals 2010

Adcirca (TM) is the first once-a-day PDE-5 inhibitor oral therapy for the

WN.com - Articles related to Carrefour 2009 net profit down 74 percent 2010